Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2023

Earnings data Q2 2023

– The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients – SAN FRANCISCO , March 22, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company , a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.

Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO , March 21, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company.  Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers' usual workflows so that it's easier to use genetic insights to inform treatment decisions.

Invitae Announces Partnership with Epic to Streamline Genetic Testing

– Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development –  – Invitae reports inducement grant under NYSE Rule 303A.08 –  SAN FRANCISCO , March 16, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn, M.D.

Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology

– New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing – SAN FRANCISCO , March 15, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023. The research reinforces the importance of universal genetic testing for patients with cancer, with much of the data highlighting the need for increased representation in clinical genetic testing data across racial, ethnic and ancestry groups that have long been underrepresented in genetic studies and databases.

Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing

Archer Aviation

Amyris

BigBear.ai Holdings

Desktop Metal

Eos Energy Enterprises

Farfetch

Penny stocks with unusual options activity today. The post 7 Penny Stocks To Watch Under $5 With Unusual Options Action appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Watch Under $5 With Unusual Options Action

Unusual options activity put these penny stocks on watch lists this week.

4 Penny Stocks To Buy For Under $5 With Unusual Options Action

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to address its convertible debt deal, fully repaid its senior secured term loan, and reduced its ongoing cash burn to $77 million for the quarter.

Invitae's Battle To Reignite Revenue Growth And Overcome Financial Challenges

Invitae Corporation (NYSE:NVTA ) TD Cowen 43rd Annual Health Care Conference Transcript March 6, 2023 1:30 PM ET Executives Ken Knight - President and CEO Roxi Wen - Chief Financial Officer Analysts Dan Brennan - Cowen and Company Dan Brennan Yes. Thank you.

Invitae Corporation (NVTA) Management Presents at TD Cowen 43rd Annual Health Care Conference (Transcript)

– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO , March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California. The policy, effective as of March 1, 2023, considers the test medically necessary for patients with stage I-IV cancer after surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression.

Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage

SAN FRANCISCO , March 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will participate in a fireside chat at the TD Cowen 43rd Annual Health Care Conference on Monday, March 6, at 1:30 p.m. Eastern. A live audio webcast of the fireside chat may be accessed by visiting the investors section of the company's website at ir.invitae.com.

Invitae to Present at the TD Cowen 43rd Annual Health Care Conference

Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates

Invitae Corporation (NYSE:NVTA ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President and Chief Executive Officer Roxi Wen - Chief Financial Officer Conference Call Participants Gabriella Gabel - Morgan Stanley Dustin Scaringe – William Blair Jeffrey Cohen - Ladenburg Operator Hello, everybody, and welcome to the Invitae Fourth Quarter 2020 Financial Results Conference Call. My name is Sam, and I will be coordinating your call today.

Invitae Corporation (NVTA) Q4 2022 Earnings Call Transcript

– In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holders to exchange 90% of their existing 2024 notes for new notes due in 2028 and equitize 10% of their holdings; Certain investors will also provide an additional $30 million of capital – – The Company will discuss this announcement during its fourth quarter and full year 2022 earnings call at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance

– Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) –  – Repaid its 2024 senior secured term loan in full, improving its balance sheet – – Company maintains cash runway through the end of 2024 – – Annual revenue grew by 12.1%; Continued to improve on key financial metrics – – Major initiatives under strategic realignment largely completed – – Guiding to low double digit pro forma revenue growth and continued expansion of non-GAAP gross margin in 2023, decreasing cash burn by over 45% from 2022 – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates

It doesn't look good, but the company isn't doomed just yet.

Down 78% in 1 Year, Is There Any Hope Left for Invitae?

SAN FRANCISCO , Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

Ally Financial

Black Hills

Shake Shack

T2 Biosystems

World Acceptance

In order for a free market to operate, investors must be willing to participate in both sides of the transaction, which brings us to the topic of the stocks to short this week. If you're feeling optimistic about the pessimistic trajectory of embattled enterprises, this list may be for you.

The 7 Best Stocks to Short This Week

The stock has been off to a red-hot start in 2023.

Is It Too Late to Buy Invitae Stock?

The company's $350 million question mark could overshadow recent progress.

Invitae Stock: Approach With Caution

– Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO , Jan. 30, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, has announced that aerospace, transportation and industrial supplies veteran William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023.

Invitae Appoints William H. Osborne to its Board of Directors

ARK Innovation ETF

Coinbase

CRISPR Therapeutics

DraftKings

Exact Sciences

Pacific Biosciences of California

Roblox

Roku

10X Genomics

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Invitae Corporation (NYSE:NVTA ) 41st Annual JPMorgan Healthcare Conference January 11, 2023 12:00 PM ET Company Participants Kenneth Knight - Chief Executive Officer Dr. Bob Nussbaum - Chief Medical Officer Roxi Wen - Chief Financial Officer Dr. Valerie Montgomery Rice - President and CEO, Morehouse School of Medicine Conference Call Participants Julia Qin - JPMorgan Chase Julia Qin All right. Good morning, everyone.

Invitae Corporation (NVTA) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)

— Approximately 12% growth year-over-year in revenues —— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —— Cash burn continued its declining trend over the past five quarters —— Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m.

Invitae Reports Preliminary 2022 Financial Results

salesforce.com

Tesla

After taking a beating last year, is now the time to load up on these stocks?

3 Growth Stocks That Haven't Been This Cheap in Years

SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president & chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 12:00 p.m.

News for Invitae Stock (NVTA)